Zacks Research Has Pessimistic View of ESPR Q3 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Zacks Research dropped their Q3 2025 earnings estimates for shares of Esperion Therapeutics in a report issued on Wednesday, February 12th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at ($0.28) EPS.

Several other brokerages have also weighed in on ESPR. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price target on the stock. JMP Securities reissued a "market outperform" rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. StockNews.com downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $6.75.

Esperion Therapeutics Trading Up 1.6 %

ESPR stock traded up $0.03 during trading on Monday, reaching $1.90. 2,027,743 shares of the stock were exchanged, compared to its average volume of 4,290,098. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The company has a market capitalization of $374.37 million, a P/E ratio of -2.97 and a beta of 1.01. The stock has a 50 day simple moving average of $2.10 and a 200-day simple moving average of $2.10.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in ESPR. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics during the third quarter worth about $27,000. Cibc World Markets Corp bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $39,000. Versor Investments LP acquired a new stake in Esperion Therapeutics during the 3rd quarter valued at $44,000. SJS Investment Consulting Inc. bought a new position in Esperion Therapeutics in the 4th quarter valued at $55,000. Finally, Crestline Management LP acquired a new position in Esperion Therapeutics in the fourth quarter worth $63,000. Institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.